[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 270,908
  • Shares Outstanding, K 23,334
  • Annual Sales, $ 40 K
  • Annual Income, $ -274,450 K
  • EBIT $ -203 M
  • EBITDA $ -196 M
  • 60-Month Beta -0.09
  • Price/Sales 8,095.60
  • Price/Cash Flow N/A
  • Price/Book 1.06

Options Overview Details

View History
  • Implied Volatility 174.91% (+5.15%)
  • Historical Volatility 90.07%
  • IV Percentile 81%
  • IV Rank 49.87%
  • IV High 277.50% on 09/22/25
  • IV Low 72.85% on 08/18/25
  • Expected Move (DTE 19) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 113
  • Volume Avg (30-Day) 71
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 816
  • Open Int (30-Day) 979
  • Expected Range 11.61 to 11.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.88
  • Number of Estimates 1
  • High Estimate $-1.88
  • Low Estimate $-1.88
  • Prior Year $-2.89
  • Growth Rate Est. (year over year) +34.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.47 +1.22%
on 06/26/26
17.65 -34.22%
on 06/01/26
-4.76 (-29.08%)
since 05/26/26
3-Month
11.47 +1.22%
on 06/26/26
25.25 -54.02%
on 04/14/26
-8.61 (-42.58%)
since 03/26/26
52-Week
8.46 +37.23%
on 06/27/25
45.00 -74.20%
on 12/22/25
+2.49 (+27.30%)
since 06/26/25

Most Recent Stories

More News
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...

LYEL : 11.61 (-7.05%)
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97% No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administration ...

LYEL : 11.61 (-7.05%)
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion 

Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxis The maximum tolerated dose has not yet been determined No difference is observed...

LYEL : 11.61 (-7.05%)
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...

LYEL : 11.61 (-7.05%)
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...

LYEL : 11.61 (-7.05%)
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances

Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated...

LYEL : 11.61 (-7.05%)
Lyell Immunopharma Announces Participation in May Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...

LYEL : 11.61 (-7.05%)
Lyell Immunopharma: Q1 Earnings Snapshot

Lyell Immunopharma: Q1 Earnings Snapshot

LYEL : 11.61 (-7.05%)
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027...

LYEL : 11.61 (-7.05%)
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...

LYEL : 11.61 (-7.05%)

Business Summary

Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 13.57
2nd Resistance Point 13.12
1st Resistance Point 12.37
Last Price 11.61
1st Support Level 11.16
2nd Support Level 10.71
3rd Support Level 9.96

See More

52-Week High 45.00
Fibonacci 61.8% 31.04
Fibonacci 50% 26.73
Fibonacci 38.2% 22.42
Last Price 11.61
52-Week Low 8.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.